10-Q: 60 Degrees Pharma Reports Q3 Loss Amid Revenue Growth, Funding

60 Degrees Pharmaceuticals, Inc. reported increased product and research revenues for Q3 2025, but continued to incur significant net losses and raised substantial capital to address ongoing going concern doubts.

Summary

• Product revenues for the nine months ended September 30, 2025, increased by 91.86% to $702,086, compared to $365,939 in the prior year.
• Research revenues surged by 804.72% to $390,630 for the nine months ended September 30, 2025, up from $43,177 in the prior year, primarily due to a new USAMMDA contract.
• The company reported a net loss attributed to 60 Degrees Pharmaceuticals, Inc. of $(5,926,599) for the nine months ended September 30, 2025, a slight increase from $(5,902,070) in the prior year.
• Net loss per common share significantly improved to $(2.92) for the nine months ended September 30, 2025, compared to $(21.74) in the prior year, influenced by a 1:5 reverse stock split.
• Cash and cash equivalents increased to $4,115,779 as of September 30, 2025, from $1,659,353 at December 31, 2024.
• Net cash used in operating activities increased to $(5,156,566) for the nine months ended September 30, 2025, from $(4,009,871) in the prior year.
• Gross profit decreased by 58.62% to $41,073 for the nine months ended September 30, 2025, with a gross loss of $(100,088) for the three months ended September 30, 2025, primarily due to higher inventory write-offs of $436,561.
• The total addressable market (TAM) for Babesiosis treatment is estimated at $1.1 billion through patent expiration in 2035, based on a 6,000-patient survey and quantitative research study.
• The company identified material weaknesses in internal control over financial reporting, including a lack of in-house technical knowledge for complex transactions, inadequate segregation of duties, and insufficient accounting staff for period-end financial disclosure and reporting.

Sentiment

Score: 3

Explanation: While the company shows significant revenue growth and pipeline progress, the persistent net losses, increased operating cash burn, substantial inventory write-offs, and explicit 'going concern' warning from auditors indicate severe financial instability. The identified material weaknesses in internal controls further compound the negative sentiment, outweighing the positives of successful capital raises and R&D advancements.

Positives

• Product revenues increased by 91.86% for the nine months ended September 30, 2025, indicating growing sales of Arakoda.
• Research revenues saw an 804.72% increase, driven by a new USAMMDA contract, diversifying revenue streams.
• Net loss per common share improved significantly from $(21.74) to $(2.92) year-over-year, partly due to capital restructuring.
• Cash and cash equivalents more than doubled to $4,115,779, providing increased liquidity.
• Successful capital raises in January, February, and July 2025, along with an At-The-Market (ATM) agreement, provided substantial net proceeds of $5,994,273.
• Progress in the Babesiosis program, including seeking MUMS designation for acute canine babesiosis and partnerships with Tulane University and Icahn School of Medicine for clinical studies.

Negatives

• The company continues to incur significant net losses, with a net loss of $(5,926,599) for the nine months ended September 30, 2025.
• Gross profit declined by 58.62% for the nine months ended September 30, 2025, and a gross loss of $(100,088) was reported for the three months ended September 30, 2025.
• Significant inventory write-offs of $436,561 for the three months ended September 30, 2025, and $436,596 for the nine months ended September 30, 2025, impacted profitability.
• Net cash used in operating activities increased by 28.60% to $(5,156,566) for the nine months ended September 30, 2025, indicating a higher cash burn rate.
• General and administrative expenses increased by 40.53% to $4,805,648 for the nine months ended September 30, 2025, driven by higher sales, advertising, promotion, and investor outreach expenses.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern for one year from the financial statements' issuance date.
• Material weaknesses in internal control over financial reporting were identified, including a lack of in-house technical knowledge for complex transactions, inadequate segregation of duties, and insufficient accounting staff.

Risks

• Ability to generate enough revenues to cover operating expenses and achieve gross profitability from its single marketed product, ARAKODA.
• Dependence on raising additional capital through third-party and related-party debt/advances, private placements, and stock offerings.
• Potential for debt or equity financing agreements to include covenants limiting the company's ability to incur additional debt, make capital expenditures, or declare dividends.
• Risk of relinquishing valuable rights to technologies, future revenue streams, research programs, or product candidates if funds are raised through collaborations.
• Inability to raise additional funds could lead to delays, limitations, reductions, or termination of product development or future commercialization efforts.
• Risks associated with developing product candidates and successfully launching and commercializing drug/device combination products.
• Uncertainty of obtaining regulatory approval for products in the United States and other markets.
• Uncertainty of broad adoption of approved products by physicians and consumers.
• Significant competition in the biopharmaceutical industry.
• Impact of higher interest rates and economic uncertainty on the company's business and financial condition.
• Potential for disruption in access to cash, cash equivalents, and investments if banks and financial institutions become insolvent.
• Concentration of credit risk with significant customers, with 89% of receivables from significant customers at September 30, 2025.
• Reliance on a sole vendor for tafenoquine inventory, posing a risk if the vendor ceases supply.
• Dilution of ownership interests for existing stockholders due to the issuance of a substantial number of shares upon exercise of warrants from the July 2025 Offering.
• Risk of delisting from The Nasdaq Capital Market if compliance with listing requirements, including the minimum bid price rule, is not maintained.

Future Outlook

Management estimates sufficient funds to remain viable through March 31, 2026, assuming no additional capital raises, based on current internal projections and recent financing activities. The company plans to fund operations through third-party and related-party debt/advances, private placements, and subsequent stock offerings until profitability or a business combination is achieved. New larger-scale production processes are expected to help keep inventory costs lower in the future, and temporary inventory write-offs are not expected to be recurring. The company is actively pursuing development programs for tick-borne fungal and other viral diseases, including tafenoquine for babesiosis, and is evaluating the impact of new accounting standards on future financial disclosures.

Management Comments

• "We estimate that we will have sufficient funds to remain viable through March 31, 2026, assuming no additional capital raises."
• "We plan to fund our operations through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent offering until such a time as the business achieves profitability or a business combination may be achieved."
• "The temporary increase in inventory write-offs was a necessary step in scaling our operations and is not expected to be recurring. Our new larger-scale production processes are expected to help keep inventory costs lower than otherwise."
• "We cannot give assurance that we can increase our cash balances or limit our cash consumption and thus maintain sufficient cash balances for our planned operations or future acquisitions."
• "We cannot assure you that we will be able to raise additional capital on acceptable terms, or at all."

Industry Context

60 Degrees Pharmaceuticals operates in the highly competitive biopharmaceutical industry, specializing in infectious diseases. The company's focus on malaria prevention (ARAKODA) and pipeline development for tick-borne and viral diseases, including babesiosis, aligns with ongoing global health challenges. The estimated $1.1 billion TAM for babesiosis treatment indicates a significant market opportunity, positioning the company to potentially capitalize on unmet medical needs. However, the industry is characterized by high R&D costs, regulatory hurdles, and intense competition, which the company acknowledges as inherent risks. The reliance on government contracts (USAMMDA) and academic partnerships (Tulane, Mount Sinai) is a common strategy for smaller biopharma firms to de-risk and advance their pipeline.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• No pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of operations were reported as of September 30, 2025.

Related Party Transactions

• The company is obligated to pay Knight Therapeutics, Inc. (a former lender) a contingent milestone payment of $10 million if Arakoda is sold or a Change of Control occurs, as per the Debt Conversion Agreement.
• A royalty equal to 3.5% of net sales is payable to Knight for a period ending upon the earlier of 10 years after the IPO closing or full conversion/redemption of Series A Preferred Stock.

Stakeholder Impact

• **Shareholders**: Face significant dilution from ongoing capital raises and warrant exercises. The 'going concern' warning and material weaknesses in internal controls pose substantial risks to investment value. However, increased revenues and pipeline progress offer potential long-term upside if profitability is achieved.
• **Employees**: The company's continued operation and development programs provide employment stability, but the 'going concern' status could create uncertainty.
• **Customers**: Continued supply of ARAKODA and development of new treatments for infectious diseases benefit patients and healthcare providers.
• **Suppliers**: The company's reliance on a sole vendor for tafenoquine API highlights a critical relationship, with potential for disruption if the vendor ceases supply.
• **Creditors**: The SBA EIDL loan is a long-term obligation, and the contingent milestone payment to Knight Therapeutics represents a significant potential liability.

Next Steps

• Continue to fund operations through third-party and related-party debt/advances, private placements, and subsequent stock offerings.
• Pursue MUMS designation from the FDA for the treatment of acute canine babesiosis.
• Advance the planned Phase II clinical study of tafenoquine in treating chronic babesiosis with Icahn School of Medicine at Mount Sinai.
• Evaluate activity of tafenoquine against lyme and bartonella bacteria through a sponsored research agreement with Tulane University.
• Replace short-dated inventory by the beginning of the second quarter of 2026.
• Address identified material weaknesses in internal control over financial reporting by employing in-house personnel with technical knowledge, improving segregation of duties, and increasing accounting staff.
• Monitor compliance with Nasdaq's continued listing requirements, including the minimum bid price rule.

Key Dates

Recommendation

Despite notable increases in product and research revenues, the company faces severe financial distress, evidenced by persistent net losses, a significant decline in gross profit, and a substantial increase in operating cash burn. The explicit 'going concern' warning from auditors, coupled with identified material weaknesses in internal control over financial reporting, indicates fundamental operational and financial instability. While recent capital raises provide short-term liquidity, they come at the cost of significant shareholder dilution, and the company's long-term viability remains highly uncertain without achieving sustained profitability. The risks associated with product development, regulatory approval, market adoption, and reliance on external financing are substantial. A seasoned investor would view these factors as overwhelmingly negative, suggesting a strong sell recommendation due to the high risk of further capital erosion and potential delisting.

Keywords

Pharmaceuticals, Biotechnology, Infectious Diseases, Malaria Prevention, Arakoda, Tafenoquine, Babesiosis, SEC Filing, 10-Q, Financial Results, Going Concern, Capital Raise, Clinical Trials, Drug Development, Corporate Governance, Nasdaq